Dahlöf B, Devereux RB, Kjeldsen SEy cols.Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002;359:995–1003.
Lindholm LH, Ibsen H y cols. Risk of new-onset diabetes in the Losartan Intervention for Endpoint reduction in hypertension study. J Hypertens 2002;20:1879–1886.
Wachtell K, Lehto M, Gerdts E y cols.Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: The LIFE study. J Am Coll Cardiol 2005;45:712–719
